Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PD-L1 bispecific CARs + CXCL10 armored CARs
- Development stage
- Preclinical
- Lead developer
- Jim Olson
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
PD-L1 bispecific CARs + CXCL10 armored CARs is an experimental cell-based immunotherapy designed for the treatment of diffuse midline gliomas (DMGs), which are aggressive and fatal brainstem tumors in children and adolescents. The therapy utilizes CAR T cells engineered to target the B7-H3 (CD276) antigen. These CAR T cells are further modified to secrete two functional components: a bispecific T cell engager (BiTE) that targets PD-L1 on tumor cells and CD3 on T cells, and the chemokine CXCL10. The BiTE is intended to convert the tumor's PD-L1-mediated immune defense into a vulnerability by creating an immune synapse, while CXCL10 serves to recruit endogenous immune cells into the tumor microenvironment to assist in tumor eradication. This multi-pronged approach aims to overcome the immunosuppressive nature of DMGs and enhance the effectiveness of the CAR T-cell therapy.
- Other names
- B7-H3-directed CAR T cells secreting PD-L1 x CD3 BiTE and CXCL10B-7-H3-directed CAR T cells secreting PD-L1 x CD3 BiTE and CXCL10B 7-H3-directed CAR T cells secreting PD-L1 x CD3 BiTE and CXCL10
02
Targets
B7-H3CD3 (T-cell surface glycoprotein CD3)CCR3 (C-C chemokine receptor type 3)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on PD-L1 bispecific CARs + CXCL10 armored CARs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PD-L1 bispecific CARs + CXCL10 armored CARs.